Curocell Seeks Amendment Approval for CRC01 Phase 3 Trial
Curocell applied to South Korea’s Ministry of Food and Drug Safety on Oct. 30, 2026, to amend the Phase 3 trial of CRC01 (anbalcell) for large B-cell lymphoma.
Curocell applied to South Korea’s Ministry of Food and Drug Safety on Oct. 30, 2026, to amend the Phase 3 trial of CRC01 (anbalcell) for large B-cell lymphoma.